DataLookout › Clinical Trial Tracker › BTK Inhibitor Pipeline

BTK Inhibitor Clinical Trials — 2026 Pipeline Tracker

BTK inhibitors are the backbone of treatment for CLL, mantle cell lymphoma, and Waldenström's — and now they're targeting autoimmune disease. Track all 144+ active BTK inhibitor trials across oncology and inflammation with daily alerts when programs advance or new studies open.

Track Free BTK Trials
144+
Active BTK inhibitor trials (2026)
69
Currently recruiting
35+
Phase 3 programs
4
FDA-approved BTK inhibitors

BTK Inhibitor Generations — How They Differ

1st Gen: Ibrutinib
Imbruvica (Pharmacyclics/AbbVie). First-in-class, covalent Cys481 binding. Highly active but off-target kinase inhibition (ITK, TEC, EGFR) causes AF, bleeding, infections. Off-patent pressure accelerating generic entry.
2nd Gen: Acalabrutinib / Zanubrutinib
Calquence (AstraZeneca), Brukinsa (BeOne/BeiGene). More selective covalent inhibitors — same mechanism, fewer off-target effects. Head-to-head vs ibrutinib showed better tolerability. Now preferred first-line in CLL.
3rd Gen: Pirtobrutinib
Jaypirca (Eli Lilly/Loxo). First non-covalent BTK inhibitor — reversible binding overcomes C481S resistance mutation. Approved for post-covalent BTK inhibitor MCL. Phase 3 vs ibrutinib head-to-head in CLL underway.
BTK Degraders (PROTACs)
BGB-16673 (BeOne). Targets BTK for proteasomal degradation — eliminates the protein entirely rather than just inhibiting it. Designed to overcome all kinase-domain resistance mutations. Phase 3 vs pirtobrutinib in development.
CNS-Penetrant BTK: Remibrutinib
Novartis. Non-covalent, highly selective, CNS-penetrant BTK inhibitor for autoimmune disease. 10+ Phase 3 programs in MS, atopic dermatitis, asthma, urticaria. Largest active BTK inhibitor trial portfolio in 2026.
Next: Nemtabrutinib, Rocbrutinib
Nemtabrutinib (Merck) — non-covalent, Phase 3 in CLL. Rocbrutinib — Phase 3 vs investigator choice in BTK-pretreated CLL/SLL. Additional non-covalent programs from multiple Chinese sponsors.

Selected Phase 3 BTK Inhibitor Trials — 2026

With 35+ Phase 3 programs, the BTK inhibitor space is one of the most active in all of clinical oncology and autoimmune research. Key programs by therapeutic area:

Oncology: CLL, MCL, Lymphoma

NCT ID Regimen Sponsor Indication Phase
NCT04075292 Acalabrutinib vs chlorambucil + rituximab (1L CLL, elderly) AstraZeneca CLL/SLL — 1st line elderly/unfit Phase 3
NCT05057494 Acalabrutinib + venetoclax vs venetoclax + obinutuzumab (1L CLL) AstraZeneca CLL/SLL — 1st line Phase 3
NCT06073821 Sonrotoclax (BCL2i) + zanubrutinib vs venetoclax + obinutuzumab BeOne Medicines CLL/SLL — 1st line Phase 3
NCT05707377 Zanubrutinib + anti-CD20 vs lenalidomide + anti-CD20 BeOne Medicines Follicular lymphoma Phase 3
NCT06846671 BGB-16673 (BTK degrader) vs investigator choice BeOne Medicines CLL/SLL after BTK inhibitor Phase 3
NCT03336333 Zanubrutinib vs BR (bendamustine + rituximab) (1L MCL) BeiGene Mantle cell lymphoma — 1st line Phase 3
NCT03462719 Ibrutinib + venetoclax vs chlorambucil + obinutuzumab (1L CLL) Janssen CLL/SLL — 1st line (GLOW) Phase 3
NCT05254743 Pirtobrutinib vs ibrutinib (head-to-head, 1L CLL) Loxo Oncology / Eli Lilly CLL/SLL — 1st line (BRUIN-CLL-322) Phase 3
NCT06136559 Nemtabrutinib (MK-1026) vs investigator choice (R/R CLL) Merck Relapsed/refractory CLL after BTK Phase 3

Autoimmune Disease: Remibrutinib (Novartis)

Novartis has built the largest BTK autoimmune trial program with 10+ Phase 3 studies of remibrutinib across CNS inflammation, dermatology, pulmonology, and nephrology.

NCT ID Comparator Indication Phase
NCT05156281 Remibrutinib vs teriflunomide Relapsing-remitting multiple sclerosis (RRMS) Phase 3
NCT05147220 Remibrutinib vs teriflunomide (confirmatory) Relapsing-remitting multiple sclerosis (RRMS) Phase 3
NCT05976243 Remibrutinib vs investigator choice Chronic spontaneous urticaria Phase 3
NCT06840392 Remibrutinib vs placebo Primary progressive multiple sclerosis (PPMS) Phase 3
NCT06868212 Remibrutinib vs dupilumab Atopic dermatitis Phase 3
NCT06846281 Remibrutinib vs ocrelizumab (switch study) Relapsing MS — switching from ocrelizumab Phase 3

Monitor the BTK inhibitor pipeline

DataLookout tracks every ibrutinib, acalabrutinib, zanubrutinib, and remibrutinib trial update — in CLL, lymphoma, and autoimmune disease. Free 14-day trial, no credit card required.

Set Up BTK Watchlist

Competitive Landscape: Top BTK Inhibitor Sponsors

The BTK inhibitor competitive landscape has shifted significantly. AbbVie/Janssen (ibrutinib/Imbruvica) are losing ground to newer covalent inhibitors as ibrutinib faces generic pressure. BeOne Medicines (formerly BeiGene) is the most active sponsor in new Phase 3 studies. Novartis dominates the autoimmune segment with remibrutinib.

Sponsor BTK Drug(s) Active Phase 3 Programs Primary Focus
Novartis Remibrutinib 16 Autoimmune (MS, AD, urticaria, asthma)
AstraZeneca Acalabrutinib (Calquence) 13 CLL, MCL, lymphoma
BeOne Medicines Zanubrutinib (Brukinsa), BGB-16673, sonrotoclax 8 CLL, lymphoma, BTK-resistant disease
Janssen / AbbVie Ibrutinib (Imbruvica) 3 CLL, lymphoma (legacy portfolio)
Eli Lilly / Loxo Pirtobrutinib (Jaypirca) 2 Post-covalent BTK MCL, CLL
Merck Nemtabrutinib (MK-1026) 1 R/R CLL after BTK inhibitor

Approved BTK Inhibitors — 2026 Reference

Drug (Generic) Brand Mechanism Sponsor Key Indications
Ibrutinib Imbruvica Covalent (1st gen) Pharmacyclics / AbbVie CLL, MCL, WM, MZL, cGVHD
Acalabrutinib Calquence Covalent (2nd gen) AstraZeneca CLL, MCL
Zanubrutinib Brukinsa Covalent (2nd gen) BeOne / BeiGene CLL, MCL, WM, MZL, DLBCL (R/R)
Pirtobrutinib Jaypirca Non-covalent (3rd gen) Eli Lilly / Loxo MCL after ≥2 prior lines incl. covalent BTKi

Key Trends in BTK Inhibitor Research, 2026

1. Non-Covalent BTK Inhibitors — Overcoming Resistance

The C481S mutation in BTK's kinase domain is the dominant resistance mechanism to first- and second-generation BTK inhibitors. Pirtobrutinib (Jaypirca) was the first non-covalent inhibitor approved specifically to address this resistance. Multiple non-covalent competitors (nemtabrutinib, rocbrutinib, sonrotoclax-combinations) are now in Phase 3, aiming to establish themselves in the growing post-covalent BTKi treatment setting.

2. BTK PROTACs — Degrading the Target Entirely

BGB-16673 (BeOne Medicines) is the first BTK PROTAC (proteolysis-targeting chimera) to reach Phase 3. Rather than inhibiting BTK, it recruits an E3 ubiquitin ligase to mark BTK for degradation by the proteasome. This approach eliminates the BTK protein entirely — including kinase-domain mutants that resist all inhibitor binding. Phase 3 vs investigator choice is now enrolling in BTK inhibitor–pretreated CLL.

3. BTK in Autoimmune Disease — The New Growth Area

BTK is expressed not only in B cells but also in myeloid cells (mast cells, macrophages, dendritic cells), making it relevant to multiple autoimmune pathologies beyond BCR signaling. Novartis's remibrutinib program is the clearest evidence of pharma's confidence in this expansion: 10+ Phase 3 trials across MS, atopic dermatitis, asthma, urticaria, IgA nephropathy, and other inflammatory conditions. If remibrutinib succeeds across even 2–3 of these, it would be one of the largest autoimmune drug launches in a decade.

4. Combination with BCL-2 Inhibitors

Zanubrutinib + sonrotoclax (BeOne's BCL-2 inhibitor) and ibrutinib/acalabrutinib + venetoclax combinations aim to achieve deep MRD-negative responses in CLL, potentially enabling fixed-duration treatment rather than continuous BTK inhibitor administration. Multiple Phase 3 trials are comparing BTKi+BCL-2i combinations against standard covalent BTK inhibitor monotherapy.

Frequently Asked Questions

What is a BTK inhibitor?
Bruton's tyrosine kinase (BTK) is a kinase enzyme critical to B-cell receptor (BCR) signaling. BTK inhibitors block this pathway — first-generation drugs (ibrutinib) bind covalently and irreversibly, second-generation (acalabrutinib, zanubrutinib) are more selective covalent inhibitors, and third-generation (pirtobrutinib) bind reversibly, allowing activity against the C481S resistance mutation.
What BTK inhibitors are currently approved?
Four BTK inhibitors are FDA-approved: ibrutinib (Imbruvica, AbbVie) — CLL, MCL, WM, MZL, cGVHD; acalabrutinib (Calquence, AstraZeneca) — CLL, MCL; zanubrutinib (Brukinsa, BeOne) — CLL, MCL, WM, MZL, certain DLBCL; pirtobrutinib (Jaypirca, Eli Lilly) — MCL after ≥2 prior lines including a covalent BTK inhibitor.
What is remibrutinib and why does it have so many trials?
Remibrutinib (LOU064) is Novartis's non-covalent, highly selective BTK inhibitor designed for autoimmune disease — not cancer. Its design prioritizes CNS penetration and a chronic-use safety profile. Novartis has invested in 10+ Phase 3 trials across MS, atopic dermatitis, chronic spontaneous urticaria, IgA nephropathy, and other conditions. It represents one of the largest clinical development programs in autoimmune disease in 2026.
What is the difference between covalent and non-covalent BTK inhibitors?
Covalent BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) form a permanent bond with Cys481 in the kinase domain — they permanently disable BTK until new protein is synthesized. Non-covalent inhibitors (pirtobrutinib, remibrutinib, nemtabrutinib) bind reversibly. The key clinical advantage of non-covalent inhibitors: they retain activity against the C481S mutation that commonly causes resistance to covalent BTK inhibitors after 2–4 years of therapy.
How can I track new BTK inhibitor clinical trials?
DataLookout monitors ClinicalTrials.gov daily and sends email alerts for new and updated BTK inhibitor trials. Track by compound, sponsor, or indication. Free accounts receive weekly summaries; paid plans unlock daily digests. Start tracking at dashboard.datalookout.com.

Related Clinical Trial Trackers